Boston Scientific (NYSE:BSX) Price Target Lowered to $100.00 at Jefferies Financial Group

Boston Scientific (NYSE:BSX) had its target price reduced by investment analysts at Jefferies Financial Group from $110.00 to $100.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Jefferies Financial Group’s price target indicates a potential upside of 53.96% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. JPMorgan Chase & Co. dropped their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Robert W. Baird lowered their target price on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Truist Financial lowered their target price on Boston Scientific from $92.00 to $90.00 and set a “buy” rating for the company in a research note on Wednesday, April 15th. Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Wednesday, February 4th. Finally, Oppenheimer lowered their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $101.43.

Boston Scientific Price Performance

Boston Scientific stock traded up $5.43 during midday trading on Wednesday, hitting $64.95. 40,395,603 shares of the company’s stock were exchanged, compared to its average volume of 16,031,291. Boston Scientific has a 52-week low of $59.38 and a 52-week high of $109.50. The stock has a 50-day moving average price of $69.04 and a two-hundred day moving average price of $86.31. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The company has a market cap of $96.53 billion, a P/E ratio of 33.48, a PEG ratio of 0.94 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the previous year, the business earned $0.75 earnings per share. The firm’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts forecast that Boston Scientific will post 3.45 earnings per share for the current year.

Insider Buying and Selling at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.34% of the stock is owned by insiders.

Institutional Trading of Boston Scientific

Several institutional investors have recently added to or reduced their stakes in BSX. Norges Bank purchased a new stake in Boston Scientific during the 4th quarter valued at $2,199,395,000. Parnassus Investments LLC lifted its holdings in shares of Boston Scientific by 42,978.9% during the 3rd quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after buying an additional 6,868,459 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Boston Scientific by 133.6% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,057,936 shares of the medical equipment provider’s stock valued at $631,135,000 after buying an additional 5,751,760 shares during the period. Egerton Capital UK LLP lifted its holdings in shares of Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after buying an additional 3,671,548 shares during the period. Finally, Maverick Capital Ltd. bought a new position in shares of Boston Scientific during the 4th quarter valued at $280,735,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat expectations: adjusted EPS $0.80 vs. $0.79 estimate and net sales $5.203B (up 11.6% y/y), showing broad revenue growth across franchises. Strong top‑line and margin metrics are the primary near‑term bullish catalyst. Boston Scientific announces results for first quarter 2026
• Positive Sentiment: Analyst support: Jefferies maintained a Buy and $100 price target, calling the company’s long‑term growth drivers intact despite near‑term guidance changes — this helps sustain investor conviction. Balancing Near-Term Guidance Cuts With Long-Term Growth Drivers: Upholding a Buy on Boston Scientific
• Positive Sentiment: Unusually large call buying ahead of the print signaled speculative bullish positioning and likely amplified intraday buying pressure. (Options volume spike reported prior to earnings.)
• Neutral Sentiment: Several firms trimmed price targets but kept Buy/Overweight ratings (e.g., Barclays lowered PT to $100; Truist and Stifel trimmed targets), reflecting a mix of cautious near‑term views and still‑positive medium‑term outlooks. Barclays price target cut
• Negative Sentiment: Guidance reset: BSX trimmed FY‑2026 EPS and Q2 guidance (Q2 EPS 0.820–0.840 vs. ~0.86 consensus; FY EPS guidance below consensus), citing slower near‑term growth — this is the main reason for analyst downward revisions and adds near‑term execution risk. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Multiple securities‑class action notices have been filed and law firms are soliciting lead plaintiffs, creating legal overhang and potential liability/settlement risk that can weigh on the stock until resolved. Bronstein, Gewirtz & Grossman investor alert

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.